Daridorexant Receives Approval for Insomnia Treatment: Daridorexant demonstrated significant reduction in daytime sleepiness among other measures

Authors :: Tran, Tiana
Walton, Roy
Source :: Drug Topics. June 2022, Vol. 166 Issue 6, p37, 1 p.
Publication Year :: 2022
Abstract: On January 7, 2022, the FDA approved daridorexant (Quviviq) for the treatment of adults with insomnia.1 The approval was based on findings from a phase 3 clinical trial program in [...]

Subjects :: Drug therapy
Testing
Evaluation
Licensing, certification and accreditation
Methods
Daridorexant -- Licensing, certification and accreditation -- Testing -- Evaluation
Clinical trials -- Methods
Insomnia -- Drug therapy
Drug approval -- Methods

Tools